Metastatic Castration-resistant Prostate Cancer
Conditions
Keywords
metastatic castration-resistant prostate cancer (mCRPC)
Brief summary
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.
Detailed description
PROpel is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting). Approximately 720 patients globally were planned to be randomized in PROpel in a 1:1 ratio to treatment with either olaparib and abiraterone or placebo and abiraterone. Enrolment had completed with a total of 796 patients randomised. Following the completion of global enrolment, the China cohort will randomise approximately 108 additional patients at sites in China, also in a 1:1 ratio. Patients will receive oral treatment with olaparib 300 mg twice daily + abiraterone 1000 mg once daily or placebo twice daily + abiraterone 1000 mg once daily. Patients in both treatment groups will also receive either prednisone or prednisolone 5 mg twice daily.
Interventions
DRUGolaparib
300 mg (2 x 150 milligrams (mg) tablets) twice daily
DRUGabiraterone acetate
1000 milligrams (mg) once daily
Sponsors
AstraZeneca
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the study protocol. 2. Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses. 3. For inclusion in i) the optional exploratory genetic research and ii) the optional biomarker research, patients must fulfill the following criteria: * Provision of informed consent for genetic research prior to collection of sample. * Provision of informed consent for biomarker research prior to collection of sample. If a patient declines to participate in the optional exploratory genetic research or the optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study. 4. Patients must be ≥18 years of age (or ≥19 years of age in South Korea) at the time of signing the informed consent form. For patients enrolled in Japan who are \<20 years of age, written informed consent should be obtained from the patient and from his legally acceptable representative. 5. Histologically or cytologically confirmed prostate adenocarcinoma. 6. Metastatic status defined as at least 1 documented metastatic lesion on either a bone scan or a computed tomography(CT)/ magnetic resonance imaging (MRI) scan. 7. First-line metastatic castration-resistant prostate cancer (mCRPC). 8. Ongoing androgen deprivation with gonadotropin-releasing hormone analogue or bilateral orchiectomy, with serum testosterone \<50 nanograms per decilitre (ng/dL) (\<2.0 nanomoles per litre (nmol/L)) within 28 days before randomisation. Patients receiving androgen deprivation therapy (ADT) at study entry should continue to do so throughout the study. 9. Candidate for abiraterone therapy with documented evidence of progressive disease. 10. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment. 11. Eastern Cooperative Oncology Group (ECOG) performance status 0-1, with no deterioration over the previous 2 weeks. 12. The participant has, in the opinion of the investigator, a life expectancy of at least 6 months. 13. Prior to randomisation, sites must confirm availability of either an archival formalin fixed, paraffin embedded (FFPE) tumour tissue sample, or a new biopsy taken during the screening window, which meets the minimum pathology and sample requirements in order to enable homologous recombination repair (HRR) status subgroup analysis of the primary endpoint radiographic progression-free survival (rPFS). If there is not written confirmation of the availability of tumour tissue prior to randomisation, the patient is not eligible for the study. 14. Male patients must use a condom during treatment and for 3 months after the last dose of olaparib+abiraterone when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.
Exclusion criteria
1. Has a known additional malignancy that has had progression or has required active treatment in the last 5 years. 2. Patients with myelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML) or with features suggestive of yelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML). 3. Clinically significant cardiovascular disease Association Class II-IV heart failure or cardiac ejection fraction measurement of \<50% during screening as assessed by echocardiography or multigated acquisition scan. 4. Planned or scheduled cardiac surgery or percutaneous coronary intervention procedure. 5. Prior revascularisation procedure (significant coronary, carotid, or peripheral artery stenosis). 6. Uncontrolled hypertension (systolic blood pressure (BP) ≥160 millimeters of mercury (mmHg) or diastolic blood pressure (BP) ≥95 millimeters of mercury (mmHg)). 7. History of uncontrolled pituitary or adrenal dysfunction. 8. Active infection or other medical condition that would make prednisone/prednisolone use contraindicated. 9. Any chronic medical condition requiring a systemic dose of corticosteroid \>10 milligrams (mg) prednisone/prednisolone per day. 10. Patients who are considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. 11. Persistent toxicities (Common Terminology Criteria for Adverse Events \[CTCAEs\] grade \>2) caused by previous cancer therapy, excluding alopecia. 12. Patients with brain metastases. A scan to confirm the absence of brain metastases is not required. 13. Patients with spinal cord compression are excluded unless they are considered to have received definitive treatment for this and have evidence of clinically stable disease for 4 weeks. 14. Patients who are unevaluable for both bone and soft tissue progression 15. Patients who are unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. 16. Immunocompromised patients 17. Patients with known active hepatitis infection (ie, hepatitis B or C). 18. Any previous treatment with Polyadenosine 5'diphosphoribose \[poly (ADP ribose)\] polymerase (PARP) inhibitor, including olaparib. 19. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment. Patients who receive palliative radiotherapy need to stop radiotherapy 1 week before randomisation. 20. Any previous exposure to a Cytochrome P450 (CYP) 17 (17α-hydroxylase/C17,20-lyase) inhibitor (eg, abiraterone, orteronel). 21. Concomitant use of known strong Cytochrome P450 (CYP) 3A inhibitors (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks. 22. Concomitant use of known strong Cytochrome P450 (CYP) 3A inducers (eg, phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine or St John's wort) or moderate Cytochrome P450 (CYP) 3A inducers (eg, bosentan, efavirenz or modafinil). The required period prior to starting study treatment is 5 weeks for phenobarbital and enzalutamide and 3 weeks for other agents. 23. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. 24. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT). 25. Participation in another clinical study with an investigational product or investigational medical devices within 1 month of randomisation. 26. History of hypersensitivity to olaparib or abiraterone, any of the excipients of olaparib or abiraterone, or drugs with a similar chemical structure or class to olaparib or abiraterone. 27. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca and Merck staff and/or staff at the study site). 28. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. 29. Previous randomisation in the present study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment | Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months) | An rPFS event is defined as progression determined by Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\] and/or Prostate Cancer Working Group 3 \[PCWG-3\] or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression. Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute ≥ 5mm increase from nadir, and/or unequivocal progression in any non target lesions, and/or any new lesion identified. Per PCWG3, progression on a bone scan is defined as 2 or more new lesions observed from the first visit after baseline compared to baseline, or from all other visits compared to first visit after baseline. A confirmatory scan is required. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Overall Survival (OS) Event | Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months). DCO3 is the final data cut-off for the OS analysis and therefore no further updates will be made. | An OS event is defined as death by any cause, regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy. |
| Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event | Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months) | A TFST (excluding radiotherapy) event is defined as the start of the first subsequent anticancer therapy after discontinuation of randomised treatment or death from any cause. |
| Number of Participants With Time to Pain Progression (TTPP) Event | Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months) | A TTPP event is defined as pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 (range 0-10, a higher score indicates worse pain) and opiate analgesic use (Analgesic quantification algorithm \[AQA\] score, range 0-7, a higher score indicates increased opioid use). For patients who are asymptomatic at baseline (average worst pain score of 0 and not taking opioids): A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits or initiation of opioid use; For patients who are symptomatic at baseline (average worst pain score \>0 and/or receiving opioids): A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits and an average worst pain score ≥4, and no decrease in average opioid use (≥1-point decrease in AQA score from a starting value of ≥2), or increase in opioid use (≥1-point increase, or ≥2-point increase if the starting value is 0) at 2 consecutive follow-up visits. |
| Number of Participants With Opiate Use | Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months) | An event for opiate use is defined as the first opiate use for cancer related pain. |
| Number of Participants With First Symptomatic Skeletal Related Event (SSRE) | Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months) | An SSRE event is defined as the first sympomatic skeletal-related event defined by * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). |
| Number of Participants With Second Progression or Death (PFS2) Event | Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months) | An event for PFS2 is defined as the second progression on next-line anticancer therapy or death, whichever occurs earlier. |
| Brief Pain Inventory-Short Form (BPI-SF) | Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months) | The BPI-SF is a validated, 15-item domain-specific instrument designed to assess the severity of pain and the impact/interference of pain on daily functions. BPI-SF worst pain, pain severity and pain interference score changes can be a minimum of -10 and a maximum of 10. A negative change from baseline value indicates improvement. |
| Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) | Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months) | Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P) total score and Functional Assessment of Cancer Therapy-General (FACT-G) total score. Total FACT-P score is the sum of Physical Well-being (PWB), Social Well-being (SWB), Emotional Well-being (EWB), Functional Well-being (FWB) and Prostate cancer subscale (PCS). FACT-P total score change from baseline values can be a minimum of -156 and a maximum of 156. A positive value indicates improvement. FACT-G total score is the sum of PWB, SWB, EWB and FWB. FACT-G Total score change from baseline values can be a minimum of -108 and a maximum of 108. A positive value indicates improvement. |
Countries
Australia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Italy, Japan, Netherlands, Slovakia, South Korea, Spain, Turkey (Türkiye), United Kingdom, United States
Contacts
PRINCIPAL_INVESTIGATORFred Saad, MD
University of Montreal Hospital Center
PRINCIPAL_INVESTIGATORNoel Clarke, M.D.
Christie Hospital Foundation Trust
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd Patients receive oral treatment with olaparib 300mg twice daily in combination with abiraterone 1000mg once daily | 399 |
| Placebo bd + Abiraterone 1000 mg qd Patients receive oral treatment with placebo twice daily in combination with abiraterone 1000mg once daily. | 397 |
| Total | 796 |
Baseline characteristics
| Characteristic | Olaparib 300 mg bd + Abiraterone 1000 mg qd | Placebo bd + Abiraterone 1000 mg qd | Total |
|---|---|---|---|
| Age, Continuous | 68.5 Years STANDARD_DEVIATION 8.5 | 69.8 Years STANDARD_DEVIATION 7.9 | 69.1 Years STANDARD_DEVIATION 8.2 |
| Age, Customized <65 | 130 Participants | 97 Participants | 227 Participants |
| Age, Customized >=65 | 269 Participants | 300 Participants | 569 Participants |
| Race/Ethnicity, Customized AMERICAN INDIAN OR ALASKA NATIVE | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized ASIAN | 66 Participants | 72 Participants | 138 Participants |
| Race/Ethnicity, Customized BLACK OR AFRICAN AMERICAN | 14 Participants | 11 Participants | 25 Participants |
| Race/Ethnicity, Customized HISPANIC OR LATINO | 68 Participants | 63 Participants | 131 Participants |
| Race/Ethnicity, Customized NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 2 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized NOT HISPANIC OR LATINO | 310 Participants | 305 Participants | 615 Participants |
| Race/Ethnicity, Customized NOT REPORTED | 22 Participants | 29 Participants | 50 Participants |
| Race/Ethnicity, Customized UNKNOWN | 12 Participants | 9 Participants | 21 Participants |
| Race/Ethnicity, Customized WHITE | 282 Participants | 275 Participants | 557 Participants |
| Region of Enrollment Australia | 28 Participants | 34 Participants | 62 Participants |
| Region of Enrollment Belgium | 4 Participants | 1 Participants | 5 Participants |
| Region of Enrollment Brazil | 54 Participants | 46 Participants | 100 Participants |
| Region of Enrollment Canada | 17 Participants | 16 Participants | 33 Participants |
| Region of Enrollment Chile | 19 Participants | 25 Participants | 44 Participants |
| Region of Enrollment Czech Republic | 18 Participants | 13 Participants | 31 Participants |
| Region of Enrollment France | 14 Participants | 25 Participants | 39 Participants |
| Region of Enrollment Germany | 14 Participants | 11 Participants | 25 Participants |
| Region of Enrollment Italy | 22 Participants | 18 Participants | 40 Participants |
| Region of Enrollment Japan | 36 Participants | 41 Participants | 77 Participants |
| Region of Enrollment Korea, Republic Of | 27 Participants | 29 Participants | 56 Participants |
| Region of Enrollment Netherlands | 16 Participants | 12 Participants | 28 Participants |
| Region of Enrollment Slovakia | 5 Participants | 13 Participants | 18 Participants |
| Region of Enrollment Spain | 19 Participants | 24 Participants | 43 Participants |
| Region of Enrollment Turkey | 39 Participants | 33 Participants | 72 Participants |
| Region of Enrollment United Kingdom | 27 Participants | 22 Participants | 49 Participants |
| Region of Enrollment USA | 40 Participants | 34 Participants | 74 Participants |
| Sex/Gender, Customized Male | 399 Participants | 397 Participants | 796 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 176 / 399 | 205 / 397 |
| other Total, other adverse events | 374 / 398 | 346 / 396 |
| serious Total, serious adverse events | 161 / 398 | 126 / 396 |
Outcome results
Primary
Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment
An rPFS event is defined as progression determined by Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\] and/or Prostate Cancer Working Group 3 \[PCWG-3\] or death (by any cause in the absence of progression), regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy prior to progression. Per RECIST v1.1, progression is defined as the sum of TLs has a 20% and absolute ≥ 5mm increase from nadir, and/or unequivocal progression in any non target lesions, and/or any new lesion identified. Per PCWG3, progression on a bone scan is defined as 2 or more new lesions observed from the first visit after baseline compared to baseline, or from all other visits compared to first visit after baseline. A confirmatory scan is required.
Time frame: Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months)
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment | 168 Participants |
| Placebo bd + Abiraterone 1000 mg qd | Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment | 226 Participants |
p-value: <0.000195% CI: [0.54, 0.81]Log Rank
Secondary
Brief Pain Inventory-Short Form (BPI-SF)
The BPI-SF is a validated, 15-item domain-specific instrument designed to assess the severity of pain and the impact/interference of pain on daily functions. BPI-SF worst pain, pain severity and pain interference score changes can be a minimum of -10 and a maximum of 10. A negative change from baseline value indicates improvement.
Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Population: Full Analysis Set (FAS), only patients with baseline assessment and at least one post treatment assessment are included in the analysis.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Brief Pain Inventory-Short Form (BPI-SF) | Change from baseline in BPI-SF worst pain | -0.09 Score | Standard Error 0.093 |
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Brief Pain Inventory-Short Form (BPI-SF) | Change from baseline in BPI-SF pain severity score | -0.08 Score | Standard Error 0.071 |
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Brief Pain Inventory-Short Form (BPI-SF) | Change from baseline in BPI-SF pain interference score | 0.01 Score | Standard Error 0.074 |
| Placebo bd + Abiraterone 1000 mg qd | Brief Pain Inventory-Short Form (BPI-SF) | Change from baseline in BPI-SF worst pain | 0.03 Score | Standard Error 0.099 |
| Placebo bd + Abiraterone 1000 mg qd | Brief Pain Inventory-Short Form (BPI-SF) | Change from baseline in BPI-SF pain severity score | -0.02 Score | Standard Error 0.076 |
| Placebo bd + Abiraterone 1000 mg qd | Brief Pain Inventory-Short Form (BPI-SF) | Change from baseline in BPI-SF pain interference score | 0.13 Score | Standard Error 0.079 |
Secondary
Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P)
Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P) total score and Functional Assessment of Cancer Therapy-General (FACT-G) total score. Total FACT-P score is the sum of Physical Well-being (PWB), Social Well-being (SWB), Emotional Well-being (EWB), Functional Well-being (FWB) and Prostate cancer subscale (PCS). FACT-P total score change from baseline values can be a minimum of -156 and a maximum of 156. A positive value indicates improvement. FACT-G total score is the sum of PWB, SWB, EWB and FWB. FACT-G Total score change from baseline values can be a minimum of -108 and a maximum of 108. A positive value indicates improvement.
Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Population: Full Analysis Set (FAS), only patients with baseline assessment and at least one post treatment assessment are included in the analysis.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) | Change from baseline in FACT-P Total | -5.84 Score | Standard Error 1.031 |
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) | Change from baseline in FACT-G Total | -5.06 Score | Standard Error 0.766 |
| Placebo bd + Abiraterone 1000 mg qd | Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) | Change from baseline in FACT-P Total | -5.30 Score | Standard Error 1.06 |
| Placebo bd + Abiraterone 1000 mg qd | Functional Assessment of Cancer Therapy- Prostate Cancer (FACT-P) | Change from baseline in FACT-G Total | -4.35 Score | Standard Error 0.787 |
Secondary
Number of Participants With First Symptomatic Skeletal Related Event (SSRE)
An SSRE event is defined as the first sympomatic skeletal-related event defined by * Use of radiation therapy to prevent or relieve skeletal symptoms. * Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral).
Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Number of Participants With First Symptomatic Skeletal Related Event (SSRE) | 46 Participants |
| Placebo bd + Abiraterone 1000 mg qd | Number of Participants With First Symptomatic Skeletal Related Event (SSRE) | 51 Participants |
p-value: 0.321295% CI: [0.55, 1.22]Log Rank
Secondary
Number of Participants With Opiate Use
An event for opiate use is defined as the first opiate use for cancer related pain.
Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Population: Randomised patients who are not on opiates at baseline
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Number of Participants With Opiate Use | 58 Participants |
| Placebo bd + Abiraterone 1000 mg qd | Number of Participants With Opiate Use | 45 Participants |
p-value: 0.309995% CI: [0.82, 1.79]Log Rank
Secondary
Number of Participants With Overall Survival (OS) Event
An OS event is defined as death by any cause, regardless of whether the patient withdraws from randomised therapy or receives another anticancer therapy.
Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months). DCO3 is the final data cut-off for the OS analysis and therefore no further updates will be made.
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Number of Participants With Overall Survival (OS) Event | 176 Participants |
| Placebo bd + Abiraterone 1000 mg qd | Number of Participants With Overall Survival (OS) Event | 205 Participants |
p-value: 0.054495% CI: [0.67, 1]Log Rank
Secondary
Number of Participants With Second Progression or Death (PFS2) Event
An event for PFS2 is defined as the second progression on next-line anticancer therapy or death, whichever occurs earlier.
Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Number of Participants With Second Progression or Death (PFS2) Event | 103 Participants |
| Placebo bd + Abiraterone 1000 mg qd | Number of Participants With Second Progression or Death (PFS2) Event | 126 Participants |
p-value: 0.053495% CI: [0.59, 0.99]Log Rank
Secondary
Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event
A TFST (excluding radiotherapy) event is defined as the start of the first subsequent anticancer therapy after discontinuation of randomised treatment or death from any cause.
Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event | 255 Participants |
| Placebo bd + Abiraterone 1000 mg qd | Number of Participants With Time to First Subsequent Anticancer Therapy or Death (TFST) Event | 285 Participants |
p-value: 0.002595% CI: [0.64, 0.9]Log Rank
Secondary
Number of Participants With Time to Pain Progression (TTPP) Event
A TTPP event is defined as pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 (range 0-10, a higher score indicates worse pain) and opiate analgesic use (Analgesic quantification algorithm \[AQA\] score, range 0-7, a higher score indicates increased opioid use). For patients who are asymptomatic at baseline (average worst pain score of 0 and not taking opioids): A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits or initiation of opioid use; For patients who are symptomatic at baseline (average worst pain score \>0 and/or receiving opioids): A ≥2 point change from baseline in average (4-7 days) worst pain score observed at 2 consecutive visits and an average worst pain score ≥4, and no decrease in average opioid use (≥1-point decrease in AQA score from a starting value of ≥2), or increase in opioid use (≥1-point increase, or ≥2-point increase if the starting value is 0) at 2 consecutive follow-up visits.
Time frame: Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)
Population: Full Analysis Set (FAS)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Olaparib 300 mg bd + Abiraterone 1000 mg qd | Number of Participants With Time to Pain Progression (TTPP) Event | 68 Participants |
| Placebo bd + Abiraterone 1000 mg qd | Number of Participants With Time to Pain Progression (TTPP) Event | 60 Participants |
p-value: 0.745695% CI: [0.75, 1.5]Log Rank